PRIME MEDICINE INCPRME
ASignal's systematic analysis rates PRME as Bearish.
Reflects the latest available analysis · analyzed Sep 27, 2026
The case on PRME
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current ratio of 3.06x indicates strong short-term liquidity
- Quick ratio of 3.00x supports near-term financial stability
- RSI at 30.2 suggests potential oversold rebound opportunity
- Cash position of $95.07M provides runway despite unprofitability
- Operating margin at -3750.87% indicates severe cost inefficiency
- Negative free cash flow of $-75.78M and negative operating cash flow
- Forward P/E of -3.29x and negative earnings reflect unprofitability
- EV/EBITDA at -2.82x and deeply negative profitability metrics
- Debt-to-equity ratio of 2.83x indicates high financial leverage
- Price momentum strongly negative at -0.088
See the full verdict on PRME
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PRME
Most investors never get a second opinion, let alone several. ASignal runs PRME past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.